TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

NCT05332496 · clinicaltrials.gov ↗

COMPLETED

Status

941

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
PROCEDURE: TACE

Sponsor

Zhongda Hospital